Vaccines for preventing influenza in healthy adults.

Si bien en el grupo mayor de 65 años, también incluido en el calendario de vacunación del Ministerio de Salud en Argentina  los estudios más serios también dicen que no hay evidencia de efectos benéficos aunque no destacan riesgos específicos, aunque si lesiones locales y un número bajo (pero existente) de casos de síndrome de Guillain-Barré. En la revisión indica que los estudios que recomiendan la vacuna están relacionados con la Industria que la producen y venden y establece que no ha habido prevención de perdida de días de trabajo y tampoco protección para complicaciones ni internaciones hospitalarias.

Vacunación Antigripal 2016

5. ¿Qué personas deben recibir la vacuna antigripal todos los años?

E. Personas mayores de 65 años

MAIN RESULTS:

We included 50 reports. Forty (59 sub-studies) were clinical trials of over 70,000 people. Eight were comparative non-RCTs and assessed serious harms. Two were reports of harms which could not be introduced in the data analysis. In the relatively uncommon circumstance of vaccine matching the viral circulating strain and high circulation, 4% of unvaccinated people versus 1% of vaccinated people developed influenza symptoms (risk difference (RD) 3%, 95% confidence interval (CI) 2% to 5%). The corresponding figures for poor vaccine matching were 2% and 1% (RD 1, 95% CI 0% to 3%). These differences were not likely to be due to chance. Vaccination had a modest effect on time off work and had no effect on hospital admissions or complication rates. Inactivated vaccines caused local harms and an estimated 1.6 additional cases of Guillain-Barré Syndrome per million vaccinations. The harms evidence base is limited.

AUTHORS’ CONCLUSIONS:

Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission.WARNING: This review includes 15 out of 36 trials funded by industry (four had no funding declaration). An earlier systematic review of 274 influenza vaccine studies published up to 2007 found industry funded studies were published in more prestigious journals and cited more than other studies independently from methodological quality and size. Studies funded from public sources were significantly less likely to report conclusions favorable to the vaccines. The review showed that reliable evidence on influenza vaccines is thin but there is evidence of widespread manipulation of conclusions and spurious notoriety of the studies. The content and conclusions of this review should be interpreted in light of this finding.

Update of

About The Author

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

16 + diecisiete =